Amgen Inc. $AMGN Holdings Trimmed by Midwest Trust Co

Midwest Trust Co reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.9% during the second quarter, Holdings Channel.com reports. The fund owned 77,424 shares of the medical research company’s stock after selling 1,492 shares during the quarter. Midwest Trust Co’s holdings in Amgen were worth $28,037,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Dogwood Wealth Management LLC grew its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the last quarter. Tower View Wealth Management LLC raised its holdings in shares of Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares in the last quarter. Manning & Napier Advisors LLC raised its holdings in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Amgen during the fourth quarter valued at approximately $34,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. Citigroup increased their price objective on Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Morgan Stanley raised their price objective on Amgen from $333.00 to $351.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Scotiabank lifted their target price on Amgen from $385.00 to $450.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $372.39.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by insiders.

Amgen Stock Performance

Amgen stock opened at $415.21 on Monday. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $421.79. The firm’s 50 day simple moving average is $370.57 and its 200-day simple moving average is $358.99. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company has a market cap of $224.48 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter last year, the business posted $6.02 EPS. The company’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts predict that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.